Synthesis, Biological Evaluation, and Molecular Docking of New Benzimidazole-1,2,3-Triazole Hybrids as Antibacterial and Antitumor Agents

References

• A. S. A. Almalki, S. Nazreen, A. M. Malebari, N. M. Ali, A. A. Elhenawy, A. A. Alghamdi, A. Ahmad, S. Y. M. Alfaifi, M. A. Alsharif, and M. M. Alam, “Synthesis and Biological Evaluation of 1,2,3-Triazole Tethered Thymol-1,3,4-Oxadiazole Derivatives as Anticancer and Antimicrobial Agents,” Pharmaceuticals 14, no. 9 (2021): 866–86. doi:10.3390/ph14090866.
   Web of Science ®Google Scholar
• J. A. Ayukekbong, M. Ntemgwa, and A. N. Atabe, “The Threat of Antimicrobial Resistance in Developing Countries: Causes and Control Strategies,” Antimicrobial Resistance & Infection Control 6, no. 1 (2017): 1–14. doi:10.1186/s13756-017-0208-x.
   Google Scholar
• Z. M. M. Alzhrani, M. M. Alam, and S. Nazreen, “Synthesis, in Silico Pharmacokinetics, and Biological Evaluation of Some New Thiazolidinedione as PPAR-γ Agonists and Antibacterial Agents,” Letters in Drug Design & Discovery 18, no. 10 (2021): 998–1008. doi:10.2174/1570180818666210427102554.
   Web of Science ®Google Scholar
• C. B. Sangani, J. A. Makawana, X. Zhang, S. B. Teraiya, L. Lin, and H. L. Zhu, “Design, Synthesis and Molecular Modeling of Pyrazole-Quinoline-Pyridine Hybrids as a New Class of Antimicrobial and Anticancer Agents,” European Journal of Medicinal Chemistry 76 (2014): 549–57. doi:10.1016/j.ejmech.2014.01.018.
   PubMed Web of Science ®Google Scholar
• M. M. Alam, A. M. Malebari, S. Nazreen, T. Neamatallah, A. S. A. Almalki, A. A. Elhenawy, R. J. Obaid, and M. A. Alsherif, “Design, Synthesis and Molecular Docking Studies of Thymol Based 1,2,3-Triazole Hybrids as Thymidylate Synthase Inhibitors and Apoptosis Inducers against Breast Cancer Cells,” Bioorganic and Medicinal Chemistry 38 (2021): 1–13.
   Web of Science ®Google Scholar
• S. Cao, F. A. Durrani, K. Toth, and Y. M. Rustum, “Se-Methylselenocysteine Offers Selective Protection against Toxicity and Potentiates the Antitumour Activity of Anticancer Drugs in Preclinical Animal Models,” British Journal of Cancer 110, no. 7 (2014): 1733–43. doi:10.1038/bjc.2014.85.
   PubMed Web of Science ®Google Scholar
• G. A. M. Eliesen, H. van Hove, M. H. Meijer, P. H. H. van den Broek, J. Pertijs, N. Roeleveld, J. van Drongelen, F. G. M. Russel, and R. Greupink, “Toxicity of Anticancer Drugs in Human Placental Tissue Explants and Trophoblast Cell Lines,” Archives of Toxicology 95, no. 2 (2021): 557–71. doi:10.1007/s00204-020-02925-w.
   PubMed Web of Science ®Google Scholar
• G. Kaur, M. Kaur, and O. Silakari, “Benzimidazoles: An Ideal Privileged Drug Scaffold for the Design of Multitargeted Anti-Inflammatory Ligands,” Mini Reviews in Medicinal Chemistry 14, no. 9 (2014): 747–67. doi:10.2174/1389557514666140820120518.
   PubMed Web of Science ®Google Scholar
• K. Starcevic, M. Kralj, K. Ester, I. Sabol, M. Grce, K. Pavelic, and G. Karminski-Zamola, “Synthesis, Antiviral and Antitumor Activity of 2-Substituted-5-Amidino-Benzimidazoles,” Bioorganic & Medicinal Chemistry 15, no. 13 (2007): 4419–26. doi:10.1016/j.bmc.2007.04.032.
   PubMed Web of Science ®Google Scholar
• H. A. Alzahrani, M. M. Alam, A. A. Elhenawy, A. M. Malebari, and S. Nazreen, “Synthesis, Antiproliferative, Docking and DFT Studies of Benzimidazole Derivatives as EGFR Inhibitors,” Journal of Molecular Structure 1253 (2022): 132265–13. doi:10.1016/j.molstruc.2021.132265.
   Web of Science ®Google Scholar
• F. A. S. Alasmary, A. M. Snelling, M. E. Zain, A. M. Alafeefy, A. S. Awaad, and N. Karodia, “Synthesis and Evaluation of Selected Benzimidazole Derivatives as Potential Antimicrobial Agents,” Molecules (Basel, Switzerland) 20, no. 8 (2015): 15206–23. doi:10.3390/molecules200815206.
   PubMed Web of Science ®Google Scholar
• M. Gaba, S. Singh, and C. Mohan, “Benzimidazole: An Emerging Scaffold for Analgesic and Anti-Inflammatory Agents,” European Journal of Medicinal Chemistry 76 (2014): 494–505. doi:10.1016/j.ejmech.2014.01.030.
   PubMed Web of Science ®Google Scholar
• D. Sharma, B. Narasimhan, P. Kumar, V. Judge, R. Narang, E. D. Clercq, and J. Balzarini, “Synthesis, Antimicrobial and Antiviral Activity of Substituted Benzimidazoles,” Journal of Enzyme Inhibition and Medicinal Chemistry 24, no. 5 (2009): 1161–8. doi:10.1080/14756360802694427.
   PubMed Web of Science ®Google Scholar
• J. Y. Xu, Y. Zeng, Q. Ran, Z. Wei, Y. Bi, Q. H. He, Q. J. Wang, S. Hu, J. Zhang, M. Y. Tang, et al, “Synthesis and Biological Activity of 2-Alkylbenzimidazoles Bearing a N-Phenylpyrrole Moiety as Novel Angiotensin II AT1 Receptor Antagonists,” Bioorganic & Medicinal Chemistry Letters 17, no. 10 (2007): 2921–6. doi:10.1016/j.bmcl.2007.02.042.
   PubMed Web of Science ®Google Scholar
• Z. M. M. Alzhrani, M. M. Alam, and S. Nazreen, “Recent Advancements on Benzimidazole: A Versatile Scaffold in Medicinal Chemistry,” Mini Reviews in Medicinal Chemistry 22, no. 2 (2022): 365–86. doi:10.2174/1389557521666210331163810.
   PubMed Web of Science ®Google Scholar
• F. Bi, S. Ji, H. Venter, J. Liu, S. J. Semple, and S. Ma, “Substitution of Terminal Amide with 1H-1,2,3-triazole: Identification of Unexpected Class of Potent Antibacterial Agents,” Bioorganic & Medicinal Chemistry Letters 28, no. 5 (2018): 884–91. doi:10.1016/j.bmcl.2018.02.001.
   PubMed Web of Science ®Google Scholar
• M. M. Alam, “1,2,3-Triazoles Hybrids as Anticancer Agents: A Review,” Archiv Der Pharmazie 355, no. 1 (2022): e2100158. ” doi:10.1002/ardp.202100158.
   PubMed Web of Science ®Google Scholar
• M. Saeedi, M. Mohammadi-Khanaposhtani, P. Pourrabia, N. Razzaghi, R. Ghadimi, S. Imanparast, M. A. Faramarzi, F. Bandarian, E. N. Esfahani, M. Safavi, et al, “Design and Synthesis of Novel Quinazolinone-1,2,3-triazole Hybrids as New Anti-diabetic Agents: In Vitro α-glucosidase Inhibition, Kinetic, and Docking Study,” Bioorganic Chemistry 83 (2019): 161–9. doi:10.1016/j.bioorg.2018.10.023.
   PubMed Web of Science ®Google Scholar
• P. Shanmugavelan, S. Nagarajan, M. Sathishkumar, A. Ponnuswamy, P. Yogeeswari, and D. Sriram, “Efficient Synthesis and in Vitro Antitubercular Activity of 1,2,3-Triazoles as Inhibitors of Mycobacterium tuberculosis,” Bioorganic & Medicinal Chemistry Letters 21, no. 24 (2011): 7273–6. doi:10.1016/j.bmcl.2011.10.048.
   PubMed Web of Science ®Google Scholar
• M. Mohammadi-Khanaposhtani, M. Mahdavi, M. Saeedi, R. Sabourian, M. Safavi, M. Khanavi, A. Foroumadi, A. Shafiee, and T. Akbarzadeh, “Design, Synthesis, Biological Evaluation, and Docking Study of Acetylcholinesterase Inhibitors: New Acridone-1,2,4-Oxadiazole-1,2,3-Triazole Hybrids,” Chemical Biology & Drug Design 86, no. 6 (2015): 1425–32. doi:10.1111/cbdd.12609.
   PubMed Web of Science ®Google Scholar
• L. S. Feng, M. J. Zheng, F. Zhao, and D. Liu, “1,2,3-Triazole Hybrids with Anti-HIV-1 Activity,” Archive Der Pharmazie 354 (2021): 200163.
   Web of Science ®Google Scholar
• M. Yang, H. Liu, Y. Zhang, X. Wang, and Z. Xu, “Moxifloxacin-Isatin Hybrids Tethered by 1,2,3-Triazole and Their Anticancer Activities,” Current Topics in Medicinal Chemistry 20, no. 16 (2020): 1461–7. doi:10.2174/1568026620666200128144825.
   PubMed Web of Science ®Google Scholar
• J. L. Abboud, C. Foces-Foces, R. Notario, R. E. Trifonov, A. P. Volovodenko, V. A. Ostrovskii, I. Alkorta, and J. Elguero, “Basicity of n-H and N-Methyl -1,2,3-Triazole in the Gas Phase, in Solution, and in the Solid State-an Experimental and Theoretical Study,” European Journal of Organic Chemistry 2001, no. 16 (2001): 3013–24. doi:10.1002/1099-0690(200108)2001:16<3013::AID-EJOC3013>3.0.CO;2-Y.
   Web of Science ®Google Scholar
• N. S. Vatmurge, B. G. Hazra, V. S. Pore, F. Shirazi, P. S. Chavan, and M. V. Deshpande, “Synthesis and Antimicrobial Activity of Beta-Lactam-Bile Acid Conjugates Linked via Triazole,” Bioorganic & Medicinal Chemistry Letters 18, no. 6 (2008): 2043–7. doi:10.1016/j.bmcl.2008.01.102.
   PubMed Web of Science ®Google Scholar
• G. Berube, “An Overview of Molecular Hybrids in Drug Discovery,” Expert Opinion in Drug Discovery 11 (2016): 281–305.
   PubMed Web of Science ®Google Scholar
• C. V. Junior, A. Danuello, V. D. Bolzani, E. J. Barreiro, and C. A. M. Fraga, “Molecular Hybridization: A Useful Tool in the Design of New Drug Prototypes,” Current Medicinal Chemistry 14 (2007): 1829–52.
   PubMed Web of Science ®Google Scholar
• V. Ivasiv, C. Albertini, A. E. Goncalves, M. Rossi, and M. L. Bolognesi, “Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases,” Current Topics in Medicinal Chemistry 19, no. 19 (2019): 1694–711. doi:10.2174/1568026619666190619115735.
   PubMed Web of Science ®Google Scholar
• L. Y. Ma, B. Wang, L. P. Pang, L.-P. M. Zhang, S. Q. Wang, Y. C. Zheng, K. P. Shao, D. Q. Xue, and H. M. Liu, “Design and Synthesis of Novel 1,2,3-triazole-pyrimidine-urea Hybrids as Potential Anticancer Agents,” Bioorganic & Medicinal Chemistry Letters 25, no. 5 (2015): 1124–8. doi:10.1016/j.bmcl.2014.12.087.
   PubMed Web of Science ®Google Scholar
• K. Bozorov, J. Zhao, and H. A. Aisa, “1,2,3-Triazole-containing Hybrids as Leads in Medicinal Chemistry: A Recent Overview,” Bioorganic & Medicinal Chemistry 27, no. 16 (2019): 3511–31. doi:10.1016/j.bmc.2019.07.005.
   PubMed Web of Science ®Google Scholar
• Z. M. M. Alzhrani, M. M. Alam, T. Neamatallah, and S. Nazreen, “Design, Synthesis and In Vitro Antiproliferative Activity of New Thiazolidinedione-1,3,4-oxadiazole Hybrids as Thymidylate Synthase Inhibitors,” Journal of Enzyme Inhibition and Medicinal Chemistry 35, no. 1 (2020): 1116–23. doi:10.1080/14756366.2020.1759581.
   PubMed Web of Science ®Google Scholar
• A. A. Alghamdi, M. M. Alam, and S. Nazreen, “In Silico ADME Predictions and in Vitro Antibacterial Evaluation of 2-Hydroxy Benzothiazole-Based 1,3,4-Oxadiazole Derivatives,” Turkish Journal of Chemistry 44, no. 4 (2020): 1068–84. doi:10.3906/kim-1912-55.
   PubMed Web of Science ®Google Scholar
• S. Nazreen, “Design, Synthesis and Molecular Docking Studies of Thiazolidinediones as PPAR-γ Agonists and Thymidylate Synthase Inhibitors,” Archiv Der Pharmazie 354, no. 9 (2021): 2100021. doi:10.1002/ardp.202100021.
   Web of Science ®Google Scholar
• M. M. Alam, S. Nazreen, A. S. A. Almalki, A. A. Elhenawy, N. I. Alsenani, S. E. I. Elbehairi, A. M. Malebari, M. Y. Alfaifi, M. A. Alsharif, and S. Y M. Alfaifi, “Naproxen Based 1,3,4-Oxadiazole Derivatives as EGFR Inhibitors: Design, Synthesis, Anticancer and Computational Studies,” Pharmaceuticals 14, no. 9 (2021): 870–96. doi:10.3390/ph14090870.
   Web of Science ®Google Scholar
• J. Stamos, M. X. Sliwkowski, and C. Eigenbrot, “Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor,” The Journal of Biological Chemistry 277, no. 48 (2002): 46265–7. doi:10.1074/jbc.M207135200.
   PubMed Web of Science ®Google Scholar
• I. Celik, G. Ayhan-Kılcıgil, B. Guven, Z. Kara, S. Gurkan-Alp, A. Karayel, and A. Onay-Besikci, “Design, Synthesis and Docking Studies of Benzimidazole Derivatives as Potential EGFR Inhibitors,” European Journal of Medicinal Chemistry 173 (2019): 240–9. doi:10.1016/j.ejmech.2019.04.012.
   PubMed Web of Science ®Google Scholar
• A. A. Abdullaziz, H. T. Abdel-Mohsen, A. M. El Kerdawy, F. A. F. Ragab, M. M. Ali, S. M. Abu-Bakr, A. S. Girgis, and H. I. El Diwani, “Design, Synthesis, Molecular Docking and Cytotoxic Evaluation of Novel 2-Furybenzimidazoles as VEGFR-2 Inhibitors,” European Journal of Medicinal Chemistry 136 (2017): 315–29. doi:10.1016/j.ejmech.2017.04.068.
   PubMed Web of Science ®Google Scholar
• W. Senapak, R. Saeeng, J. Jaratjaroonphong, V. Promarak, and U. Sirion, “Metal-Free Selective Synthesis of 2-Substituted Benzimidazoles Catalyzed by Bronsted Acidic Ionic Liquid: Convenient Access to One-Pot Synthesis of N-Alkylated 1,2-Disubstituted Benzimidazoles,” Tetrahedron 75, no. 26 (2019): 3543–52. doi:10.1016/j.tet.2019.05.014.
   Web of Science ®Google Scholar
• S. Shafi, M. M. Alam, N. Mulakayala, C. Mulakayala, G. Vanaja, A. M. Kalle, R. Pallu, and M. S. Alam, “Synthesis of Novel 2-Mercapto Benzothiazole and 1,2,3-Triazole Based Bis-Heterocycles: Their Anti-Inflammatory and Anti-Nociceptive Activities,” European Journal of Medicinal Chemistry 49 (2012): 324–33. doi:10.1016/j.ejmech.2012.01.032.
   PubMed Web of Science ®Google Scholar
• D. Domyati, S. A. Zabin, A. A. Elhenawy, and M. Abdelbaset, “Preparation, Antimicrobial Activity and Docking Study of Vanadium Mixed Ligand Complexes Containing 4-Amino-5-Hydrazinyl-4h-1,2,4-Triazole-3-Thiol and Aminophenol Derivatives,” Processes 9, no. 6 (2021): 1008–119. doi:10.3390/pr9061008.
   Web of Science ®Google Scholar
• R. Srivastava, S. K. Gupta, F. Naaz, P. S. S. Gupta, M. Yadav, V. K. Singh, A. Singh, M. K. Rana, S. K. Gupta, D. Schols, et al, “Alkylated Benzimidazoles: Design, Synthesis, Docking, DFT Analysis, ADMET Property, Molecular Dynamics and Activity against HIV and YFV,” Computational Biology and Chemistry 89 (2020): 107400. doi:10.1016/j.compbiolchem.2020.107400.
   PubMed Web of Science ®Google Scholar
• M. El-Gaafary, T. Syrovets, H. M. Mohamed, A. A. Elhenawy, A. M. El-Agrody, A. E. G. E. Amr, H. A. Ghabbour, and A. A. Almehizia, “Synthesis, Cytotoxic Activity, Crystal Structure, DFT Studies and Molecular Docking of 3-Amino-1-(2,5-Dichlorophenyl)-8-Methoxy-1H-Benzo[f]Chromene-2-Carbonitrile,” Crystals 11, no. 2 (2021): 184. doi:10.3390/cryst11020184.
   Web of Science ®Google Scholar
• A. A. Elhenawy, L. M. Al-Harbi, G. O. Moustafa, M. A. El-Gazzar, R. F. Abdel-Rahman, and A. E. Salim, “Synthesis, Comparative Docking, and Pharmacological Activity of Naproxen Amino Acid Derivatives as Possible Anti-Inflammatory and Analgesic Agents,” Drug Design, Development and Therapy 13 (2019): 1773–90. doi:10.2147/DDDT.S196276.
   PubMed Web of Science ®Google Scholar